What type of study is this?

This is a Quantitative Study study.

September 29, 2025

Abstract B052: Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023)

Key Points

Thromboembolism-related deaths have been increasing among pancreatic cancer patients, particularly in males, Black population, and urban areas.
Overall age-adjusted mortality rates increased from 0.31 in 1999 to 0.65 in 2023, with notable spikes in certain years.
Analysis utilized death certificates from 1999 to 2023 and applied join-point regression to evaluate trends in mortality rates.
Findings highlight urgent needs for equitable public health strategies to address increasing mortality rates among high-risk groups.

Abstract

Abstract Background: Pancreatic cancer and thromboembolism frequently coexist, posing significant challenges in clinical management. The interplay between these conditions can exacerbate hemodynamic instability and influence treatment outcomes. This study aims to assess or evaluate the impact of thromboembolism related mortalities among patients with pancreatic cancer. Methods: We analyzed adults aged 25 years death certificates from the CDC-WONDER database with pancreatic cancer (ICD-10 codes: C25) and thromboembolism (ICD-10 codes: I26, I80, and I82) from 1999-2023. Age-adjusted mortality rates (AAMR) per 100, 000 were calculated, and trends were analyzed by gender, race, region and metropolitan status. Join-point regression was used to calculate annual percentage changes (APC) with 95 % confidence intervals (CI). Results: A total of 24, 870 deaths were attributed to pancreatic cancer and thromboembolism related mortalities in individuals from 1999 to 2023. The AAMR increased from 0. 31 in 1999 to 0. 42 in 2011 (APC: 2. 7; 95% CI: 1. 91-3. 5), then decreased to 0. 4 in 2015 (APC: -1. 34; 95% CI: -6. 77 to 4. 40), and ultimately increased to 0. 65 in 2023 (APC: 7. 39; 95% CI: 6. 0-8. 81) with an overall AAPC (3. 55; 95% CI: 2. 48-4. 62). In terms of gender, both sexes show increment with higher AAMRs (1999-2023) in males from 0. 35 to 0. 76 (AAPC: 3. 4; 95% CI: 2. 84-3. 97) compared to females from 0. 27 to 0. 58 (AAPC: 3. 61; 95% CI: 2. 02-5. 22). From 1999 to 2023, Non-Hispanic (NH) Black or African American displayed the highest AAMR (0. 47-1. 09), followed by NH White (0. 29-0. 64), and Hispanic or Latino (0. 21-0. 45). Geographically, The AAMR for the Northeast ranged from 0. 35 in 1999 to 0. 67 in 2023, followed by the Midwest (0. 31-0. 67), the South (0. 3-0. 67), and the West (0. 29-0. 6). Metropolitan areas had the highest overall AAMR (0. 4) while Nonmetropolitan areas had the lowest (0. 38). Conclusion: Mortalities related to pancreatic cancer and thromboembolism have increased, with highest rates among males, Black population, and those in Northeastern and urban U. S. , requiring targeted, equitable public health strategies. Citation Format: Sravani Bhavanam, Hakim Wazir, Nayanika Tummala, Amna Amjad, Diya Rathi, Aqsa Shaikh, Yassar Ul. Mulk. Trends in Thromboembolism-Related Mortality Among Patients with Pancreatic Cancer in the United States: A CDC WONDER Analysis (1999–2023) abstract. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85 (18Suppl₃): Abstract nr B052.

Bookmark

Cite This Study

Bhavanam et al. (Sun,) studied this question.

synapsesocial.com/papers/68da58e0c1728099cfd1179e https://doi.org/https://doi.org/10.1158/1538-7445.pancreatic25-b052

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark